An analysis of the influencing factors of false negative autoantibodies in patients with non-small cell lung cancer
Ailin Wang1, Ying Hao1, Yunlong Huo2
1Department of Gerontology and Geriatrics, Sheng Jing Hospital of China Medical University, Shenyang, China.
Frontiers in Oncology
|May 27, 2024
Summary
Seven autoantibodies show clinical significance in non-small cell lung cancer (NSCLC) diagnosis. However, consider potential false-negative results in patients with specific clinical factors to prevent missed diagnoses.
Area of Science:
- Oncology
- Immunology
- Biomarker Discovery
Background:
- Non-small cell lung cancer (NSCLC) diagnosis relies on various methods.
- Autoantibodies are emerging as potential biomarkers for cancer detection.
- Understanding autoantibody profiles can aid in early NSCLC diagnosis and management.
Purpose of the Study:
- To evaluate the clinical significance of seven specific autoantibodies in NSCLC patients.
- To identify factors associated with autoantibody expression and false-negative results.
Main Methods:
- Serum samples from 502 NSCLC patients were analyzed using ELISA for seven autoantibodies.
- Correlations between autoantibody levels and clinicopathological factors were assessed.
- Comparison of false-negative and positive groups identified influencing factors.
Main Results:
- Specific autoantibodies (P53, PGP9.5, SOX2, MAGE) showed correlations with clinicopathological features like lobulation, sex, vascular convergence, pathological type, and clinical stage.
- False-negative results were more common in patients with ground-glass nodules, no enlarged lymph nodes, no vascular convergence, and low PD-L1 expression (<1%).
Conclusions:
- The detection of these seven autoantibodies holds clinical significance for NSCLC patients.
- The study highlights the importance of considering autoantibody sensitivity limitations to avoid misdiagnosis.
